Effectiveness of Etoricoxib as an Additive Analgesic to Epidural Analgesia in Colon or Rectal Fast-track Surgery
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Post-operative pain after laparoscopic colon and rectal surgery in fast-track design.
A fast-track program is an evidence-based, multimodal approach for patients undergoing surgery to reduce perioperative morbidity, hospital stay and cost and to increase patient centered well-being. Optimized pain relief is a core component of any fast-track regimen.
In this context epidural analgesia has become the standard of care for early postoperative pain therapy.
However, it is debated whether non-opioid analgesics should be given as adjuncts when epidural analgesia is already present.
The purpose of this study is to demonstrate that the administration of etoricoxib 120mg additionally to the clinical routine therapy (epidural catheter) reduces the post-operative pain level during movement after laparoscopic colon surgery in the fast-track design.
| Condition | Intervention | Phase |
|---|---|---|
|
Post-operative Pain |
Drug: Arcoxia®120 mg Drug: P Tablet White Lichtenstein |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | A Double-blind, Randomized, Placebo Controlled Study to Evaluate the Effectiveness of Etoricoxib as an Additive Analgesic to Epidural Analgesia in Colon or Rectal Fast-track Surgery |
- Primary end point of the study is the average pain level (scale 0-10) in the area of surgery during movement (walking a fixed number of steps) under active epidural analgesia, at the third day following laparoscopic colon or rectal surgery. [ Time Frame: third postoperative day ] [ Designated as safety issue: Yes ]To demonstrate that the administration of etoricoxib 120mg additionally to the clinical routine therapy (epidural catheter) reduces the post-operative pain level during movement at the thrid day after laparoscopic colon or rectal surgery in the fast-track design.
- Post-operative pain level during movement in the first 2 days after laparoscopic colon or rectal surgery. [ Time Frame: in the first 2 days after laparoscopic colon or rectal surgery ] [ Designated as safety issue: Yes ]
- Post-operative pain level during rest in the first 2 days after laparoscopic colon or rectal surgery. [ Time Frame: in the first 2 days after laparoscopic colon or rectal surgery ] [ Designated as safety issue: Yes ]
- Post-operative pain level during rest and movement from the third until the fifth day after laparoscopic colon or rectal surgery (one day after epidural catheter removal) [ Time Frame: one day after epidural catheter removal ] [ Designated as safety issue: Yes ]
- Incidence of pain events and the average pain intensity in body parts outside of the area of operations. [ Time Frame: study period ] [ Designated as safety issue: Yes ]
- Incidence of new organ dysfunctions, side effects, frequency and amount of intake of rescue medication. [ Time Frame: study period ] [ Designated as safety issue: Yes ]
- Postoperative LOS [ Time Frame: period of hospital stay ] [ Designated as safety issue: No ]
- Patients level of satisfaction [ Time Frame: study period ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 90 |
| Study Start Date: | March 2011 |
| Estimated Study Completion Date: | September 2014 |
| Estimated Primary Completion Date: | September 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Arcoxia® 120 mg |
Drug: Arcoxia®120 mg
Arcoxia® over encapsulated 120 mg; Perioperatively 6 days 1 tablet (Arcoxia® 120 mg) for oral use
Other Name: Etoricoxib
|
| Placebo Comparator: Sugar pill |
Drug: P Tablet White Lichtenstein
P Tablet White Lichtenstein over encapsulated; Perioperatively 6 days 1 tablet for oral use
|
Detailed Description:
A fast-track program is an evidence-based, multimodal approach for patients undergoing surgery to reduce perioperative morbidity, hospital stay and cost and to increase patient centered well-being. Particularly in visceral surgery of the colon it is gaining widespread acceptance (Schwenk 2009). Optimized pain relief is a core component of any fast-track regimen (Kehlet and Wilmore 2008). In this context epidural analgesia has become the standard of care for early postoperative pain therapy (Hasenberg 2009), providing superior pain relief compared to parenteral opioids (Block 2001).
The open question of analgesic adjuncts to epidural analgesia. However, it is debated whether non-opioid analgesics should be given as adjuncts when epidural analgesia is already present. Some studies have found reduced pain using NSAID as adjunct (Scott 1994), leading to a positive recommendation in the German guidelines for postoperative pain therapy (S3-Leitlinie). However, other studies (Mogensen 1992) have not found an effect of non-opioids in addition to epidural analgesia. Further studies are also needed to assess whether nonopioid adjuncts can facilitate the change from epidural to systemic analgesia (typically on the 2nd or 3rd postoperative day) and reduce opioid consumption during the days after catheter removal.
Fast-track surgery is a multi-model process, and every step in this process needs to be fine-tuned to yield best results (Langelotz 2005). Until now studies have compared only groups with either epidural or systemic analgesia, but for optimal recovery a sequential approach with a combination of both is probably a better choice. A typical multimodal analgesia regimen after removal of an epidural at our institution consists of acetaminophen and ibuprofen. Opioids are avoided if possible, but are added if needed. An improved non-opioid analgesia regimen is a sought-after goal in this fast-track-phase. The study is controlled in terms of the type of surgery (laparoscopic colon and rectal surgery) and all factors of the multimodal analgesia treatment.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- aged 18 or over
- written informed consent
- no inclusion in other medical studies according to the AMG (German drug law) during the study period
- realization of colon or rectal surgery in the fast track design after clinical standards including an epidural catheter
Exclusion Criteria:
- ASA status IV-V
- allergy against etoricoxib, other components or other NSAID
- coronary heart disease
- heart insufficiency NYHA II-IV
- cerebrovascular disease
- peripheral arterial occlusive disease
- untreated arterial hypertonus
- active peptic ulcera or active gastrointestinal bleeding
- minor to severe liver dysfunction (beginning from Child - Plugh - Classification A)
- kidney insufficiency
- inflammatory bowl disease
- pregnancy (positive hCG laboratory test) or lactation
- Women of child-bearing potential who are not using a highly effective contraception method with a pearl-index < 1 during study participation and for at least 3 consecutive months after study inclusion.
- placement in an institution on order of an official authority
- missing consent for saving and passing on pseudonymous data
- hereditary galactose-intolerance, lactase deficit, glucose-galactose-malabsorption
- no correct epidural catheter placement within 48 h after surgery
Contacts and Locations| Contact: Claudia Spies, MD Prof. | +49 (0) 30 450 551 001 | claudia.spies@charite.de |
| Germany | |
| Department of Anesthesiology and Intensive Care Medicine, Campus Virchow Klinikum/Campus Charité Mitte, Charité Universitätsmedizin | Recruiting |
| Berlin, Germany, 13353 | |
| Contact: Claudia Spies, MD Prof. +49 (0) 30 450 551 001 claudia.spies@charite.de | |
| Department of Anesthesiology, Sana-Klinikum Lichtenberg, Oskar-Ziethen-Krankenhaus | Recruiting |
| Berlin, Germany, 10365 | |
| Contact: Yvonne Tock, MD +49 -30 5518-0 | |
| Principal Investigator: Yvonne Tock, MD | |
| Department of Anesthesiology, Johannes Wesling Klinikum Minden Mühlenkreiskliniken (AöR) | Recruiting |
| Minden, Germany, 32429 | |
| Contact: Bernd Bachmann-Mennenga, MD Prof. +49 0571 790 4401 bbm@muehlenkreiskliniken.de | |
| Principal Investigator: Bernd Bachmann-Mennenga, MD Prof. | |
| Study Director: | Claudia Spies, MD, Prof. | Dept. of Anesthesiology and Intensive Care, Charité, Universitätsmedizin Berlin |
More Information
No publications provided
| Responsible Party: | Claudia Spies, Prof. MD, Director of the Dept. of Anaesthesiology and Intensive Care Medicine, CVK, CCM, Charite University, Berlin, Germany, Charite University, Berlin, Germany |
| ClinicalTrials.gov Identifier: | NCT01259830 History of Changes |
| Other Study ID Numbers: | Etoricoxib-fast-track |
| Study First Received: | December 13, 2010 |
| Last Updated: | May 17, 2013 |
| Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
Keywords provided by Charite University, Berlin, Germany:
|
fast-track colon or rectal surgery pain relief |
Additional relevant MeSH terms:
|
Pain, Postoperative Postoperative Complications Pathologic Processes Pain Signs and Symptoms Analgesics Etoricoxib Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Pharmacologic Actions |
Central Nervous System Agents Therapeutic Uses Cyclooxygenase 2 Inhibitors Cyclooxygenase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Anti-Inflammatory Agents Antirheumatic Agents |
ClinicalTrials.gov processed this record on May 23, 2013